[Clinical characteristics of liver damage in 30 patients with severe coronavirus disease 2019 in Sichuan area].
Identifieur interne : 000058 ( Main/Exploration ); précédent : 000057; suivant : 000059[Clinical characteristics of liver damage in 30 patients with severe coronavirus disease 2019 in Sichuan area].
Auteurs : Tianlong Li [République populaire de Chine] ; Chao Deng [Oman] ; Qing Du [Oman] ; Ruiming Yue [République populaire de Chine] ; Sen Lu [République populaire de Chine] ; Hong Chen [Oman] ; Yang Guo [République populaire de Chine] ; Xiaobo Huang [République populaire de Chine]Source :
- Zhonghua wei zhong bing ji jiu yi xue [ 2095-4352 ] ; 2020.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen (MeSH), Antiviraux (usage thérapeutique), Association médicamenteuse (MeSH), Chine (épidémiologie), Humains (MeSH), Indice de gravité de la maladie (MeSH), Infections à coronavirus (complications), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (épidémiologie), Lopinavir (usage thérapeutique), Maladies du foie (physiopathologie), Maladies du foie (virologie), Mâle (MeSH), Pandémies (MeSH), Pneumopathie virale (complications), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (épidémiologie), Ritonavir (usage thérapeutique), Résultat thérapeutique (MeSH), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Études rétrospectives (MeSH).
- MESH :
- physiopathologie : Maladies du foie.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Antiviraux, Infections à coronavirus, Lopinavir, Pneumopathie virale, Ritonavir.
- virologie : Maladies du foie.
- épidémiologie : Chine, Infections à coronavirus, Pneumopathie virale.
- Adulte d'âge moyen, Association médicamenteuse, Humains, Indice de gravité de la maladie, Mâle, Pandémies, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Études rétrospectives.
- Wicri :
- geographic : République populaire de Chine.
English descriptors
- KwdEn :
- Aged (MeSH), Aged, 80 and over (MeSH), Antiviral Agents (therapeutic use), China (epidemiology), Coronavirus Infections (complications), Coronavirus Infections (drug therapy), Coronavirus Infections (epidemiology), Drug Combinations (MeSH), Humans (MeSH), Liver Diseases (physiopathology), Liver Diseases (virology), Lopinavir (therapeutic use), Male (MeSH), Middle Aged (MeSH), Pandemics (MeSH), Pneumonia, Viral (complications), Pneumonia, Viral (drug therapy), Pneumonia, Viral (epidemiology), Retrospective Studies (MeSH), Ritonavir (therapeutic use), Severity of Illness Index (MeSH), Treatment Outcome (MeSH).
- MESH :
- chemical , therapeutic use : Antiviral Agents, Lopinavir, Ritonavir.
- geographic , epidemiology : China.
- complications : Coronavirus Infections, Pneumonia, Viral.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- physiopathology : Liver Diseases.
- virology : Liver Diseases.
- Aged, Aged, 80 and over, Drug Combinations, Humans, Male, Middle Aged, Pandemics, Retrospective Studies, Severity of Illness Index, Treatment Outcome.
Abstract
OBJECTIVE
To describe the characteristics of liver damage in severe coronavirus disease 2019 (COVID-19) patients in Sichuan area and the effect of antiviral drugs on liver function.
METHODS
The clinical data of severe COVID-19 patients admitted to Chengdu Public Health Clinical Medical Center from January 21 to February 24, 2020 were retrospectively collected, including demographic data, clinical manifestations and liver function changes within 1 week after admission to intensive care unit (ICU). The changes of liver function during the course of disease in severe COVID-19 patients were analyzed and summarized, and group analysis was performed.
RESULTS
A total of 30 COVID-19 patients with complete clinical data were enrolled. The incidence of severe COVID-19 in elderly men was higher (60.0%), with median age of 61 (47, 79) years old, and those aged 80 or above accounted for 23.3%. The severe COVID-19 patients mainly presented with respiratory symptoms such as fever (96.7%), cough (80.0%) and dyspnea (66.7%). The alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBil) and prothrombin time (PT) of 30 patients were increased to various degrees within 1 week after ICU admission, and albumin (ALB) was decreased. (1) The patients were divided into two groups according to whether to take lopinavir/ritonavir (kaletra). It was shown that the incidence of liver dysfunction in patients taking kaletra was significantly higher than those who did not take kaletra (7-day abnormal rate of ALT was 54% vs. 33%, the abnormal rate of AST was 38% vs. 33%, the abnormal rate of TBil was 8% vs. 0%), but there were no statistical differences (all P > 0.05). (2) The patients were divided into normal dose group (500 mg, twice a day, n = 19) and reduced dose group (250 mg, twice a day, n = 5) according to the dosage of kaletra. It was shown that patients taking low-dose kaletra had a smaller effect on liver function within 1 week after ICU admission than those receiving normal dosage, and ALB, TBil in the reduced dose group were significantly lower than those in the normal dose group on the 2nd day after ICU admission [ALB (g/L): 33.3±2.0 vs. 37.5±4.0, TBil (μmol/L): 6.3±3.3 vs. 11.3±4.8, both P < 0.05].
CONCLUSIONS
Severe COVID-19 patients in Sichuan area suffered obvious liver damage in the early course of the disease and have a slower recovery. It is important to pay attention to avoid using drugs that can aggravate liver damage while treating the disease. If there is no alternative drug, liver protection treatment should be considered appropriately.
DOI: 10.3760/cma.j.cn121430-20200513-00656
PubMed: 32912404
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Clinical characteristics of liver damage in 30 patients with severe coronavirus disease 2019 in Sichuan area].</title><author><name sortKey="Li, Tianlong" sort="Li, Tianlong" uniqKey="Li T" first="Tianlong" last="Li">Tianlong Li</name><affiliation wicri:level="1"><nlm:affiliation>Department of Critical Care Medicine, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu 610000, Sichuan, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Critical Care Medicine, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu 610000, Sichuan</wicri:regionArea><wicri:noRegion>Sichuan</wicri:noRegion></affiliation></author><author><name sortKey="Deng, Chao" sort="Deng, Chao" uniqKey="Deng C" first="Chao" last="Deng">Chao Deng</name><affiliation wicri:level="1"><nlm:affiliation>Department of Critical Care Medicine, Chengdu Public Health Clinical Medical Center, Chengdu 610000, Sichuan, China. Corresponding author: Huang Xiaobo, Email: drhuangxb@163.com.</nlm:affiliation><country wicri:rule="url">Oman</country><wicri:regionArea>Department of Critical Care Medicine, Chengdu Public Health Clinical Medical Center, Chengdu 610000, Sichuan, China. Corresponding author: Huang Xiaobo</wicri:regionArea><wicri:noRegion>China. Corresponding author: Huang Xiaobo</wicri:noRegion></affiliation></author><author><name sortKey="Du, Qing" sort="Du, Qing" uniqKey="Du Q" first="Qing" last="Du">Qing Du</name><affiliation wicri:level="1"><nlm:affiliation>Department of Critical Care Medicine, Chengdu Public Health Clinical Medical Center, Chengdu 610000, Sichuan, China. Corresponding author: Huang Xiaobo, Email: drhuangxb@163.com.</nlm:affiliation><country wicri:rule="url">Oman</country><wicri:regionArea>Department of Critical Care Medicine, Chengdu Public Health Clinical Medical Center, Chengdu 610000, Sichuan, China. Corresponding author: Huang Xiaobo</wicri:regionArea><wicri:noRegion>China. Corresponding author: Huang Xiaobo</wicri:noRegion></affiliation></author><author><name sortKey="Yue, Ruiming" sort="Yue, Ruiming" uniqKey="Yue R" first="Ruiming" last="Yue">Ruiming Yue</name><affiliation wicri:level="1"><nlm:affiliation>Department of Critical Care Medicine, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu 610000, Sichuan, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Critical Care Medicine, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu 610000, Sichuan</wicri:regionArea><wicri:noRegion>Sichuan</wicri:noRegion></affiliation></author><author><name sortKey="Lu, Sen" sort="Lu, Sen" uniqKey="Lu S" first="Sen" last="Lu">Sen Lu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Critical Care Medicine, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu 610000, Sichuan, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Critical Care Medicine, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu 610000, Sichuan</wicri:regionArea><wicri:noRegion>Sichuan</wicri:noRegion></affiliation></author><author><name sortKey="Chen, Hong" sort="Chen, Hong" uniqKey="Chen H" first="Hong" last="Chen">Hong Chen</name><affiliation wicri:level="1"><nlm:affiliation>Department of Critical Care Medicine, Chengdu Public Health Clinical Medical Center, Chengdu 610000, Sichuan, China. Corresponding author: Huang Xiaobo, Email: drhuangxb@163.com.</nlm:affiliation><country wicri:rule="url">Oman</country><wicri:regionArea>Department of Critical Care Medicine, Chengdu Public Health Clinical Medical Center, Chengdu 610000, Sichuan, China. Corresponding author: Huang Xiaobo</wicri:regionArea><wicri:noRegion>China. Corresponding author: Huang Xiaobo</wicri:noRegion></affiliation></author><author><name sortKey="Guo, Yang" sort="Guo, Yang" uniqKey="Guo Y" first="Yang" last="Guo">Yang Guo</name><affiliation wicri:level="1"><nlm:affiliation>Department of Critical Care Medicine, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu 610000, Sichuan, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Critical Care Medicine, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu 610000, Sichuan</wicri:regionArea><wicri:noRegion>Sichuan</wicri:noRegion></affiliation></author><author><name sortKey="Huang, Xiaobo" sort="Huang, Xiaobo" uniqKey="Huang X" first="Xiaobo" last="Huang">Xiaobo Huang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Critical Care Medicine, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu 610000, Sichuan, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Critical Care Medicine, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu 610000, Sichuan</wicri:regionArea><wicri:noRegion>Sichuan</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32912404</idno><idno type="pmid">32912404</idno><idno type="doi">10.3760/cma.j.cn121430-20200513-00656</idno><idno type="wicri:Area/Main/Corpus">000269</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000269</idno><idno type="wicri:Area/Main/Curation">000269</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000269</idno><idno type="wicri:Area/Main/Exploration">000269</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Clinical characteristics of liver damage in 30 patients with severe coronavirus disease 2019 in Sichuan area].</title><author><name sortKey="Li, Tianlong" sort="Li, Tianlong" uniqKey="Li T" first="Tianlong" last="Li">Tianlong Li</name><affiliation wicri:level="1"><nlm:affiliation>Department of Critical Care Medicine, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu 610000, Sichuan, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Critical Care Medicine, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu 610000, Sichuan</wicri:regionArea><wicri:noRegion>Sichuan</wicri:noRegion></affiliation></author><author><name sortKey="Deng, Chao" sort="Deng, Chao" uniqKey="Deng C" first="Chao" last="Deng">Chao Deng</name><affiliation wicri:level="1"><nlm:affiliation>Department of Critical Care Medicine, Chengdu Public Health Clinical Medical Center, Chengdu 610000, Sichuan, China. Corresponding author: Huang Xiaobo, Email: drhuangxb@163.com.</nlm:affiliation><country wicri:rule="url">Oman</country><wicri:regionArea>Department of Critical Care Medicine, Chengdu Public Health Clinical Medical Center, Chengdu 610000, Sichuan, China. Corresponding author: Huang Xiaobo</wicri:regionArea><wicri:noRegion>China. Corresponding author: Huang Xiaobo</wicri:noRegion></affiliation></author><author><name sortKey="Du, Qing" sort="Du, Qing" uniqKey="Du Q" first="Qing" last="Du">Qing Du</name><affiliation wicri:level="1"><nlm:affiliation>Department of Critical Care Medicine, Chengdu Public Health Clinical Medical Center, Chengdu 610000, Sichuan, China. Corresponding author: Huang Xiaobo, Email: drhuangxb@163.com.</nlm:affiliation><country wicri:rule="url">Oman</country><wicri:regionArea>Department of Critical Care Medicine, Chengdu Public Health Clinical Medical Center, Chengdu 610000, Sichuan, China. Corresponding author: Huang Xiaobo</wicri:regionArea><wicri:noRegion>China. Corresponding author: Huang Xiaobo</wicri:noRegion></affiliation></author><author><name sortKey="Yue, Ruiming" sort="Yue, Ruiming" uniqKey="Yue R" first="Ruiming" last="Yue">Ruiming Yue</name><affiliation wicri:level="1"><nlm:affiliation>Department of Critical Care Medicine, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu 610000, Sichuan, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Critical Care Medicine, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu 610000, Sichuan</wicri:regionArea><wicri:noRegion>Sichuan</wicri:noRegion></affiliation></author><author><name sortKey="Lu, Sen" sort="Lu, Sen" uniqKey="Lu S" first="Sen" last="Lu">Sen Lu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Critical Care Medicine, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu 610000, Sichuan, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Critical Care Medicine, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu 610000, Sichuan</wicri:regionArea><wicri:noRegion>Sichuan</wicri:noRegion></affiliation></author><author><name sortKey="Chen, Hong" sort="Chen, Hong" uniqKey="Chen H" first="Hong" last="Chen">Hong Chen</name><affiliation wicri:level="1"><nlm:affiliation>Department of Critical Care Medicine, Chengdu Public Health Clinical Medical Center, Chengdu 610000, Sichuan, China. Corresponding author: Huang Xiaobo, Email: drhuangxb@163.com.</nlm:affiliation><country wicri:rule="url">Oman</country><wicri:regionArea>Department of Critical Care Medicine, Chengdu Public Health Clinical Medical Center, Chengdu 610000, Sichuan, China. Corresponding author: Huang Xiaobo</wicri:regionArea><wicri:noRegion>China. Corresponding author: Huang Xiaobo</wicri:noRegion></affiliation></author><author><name sortKey="Guo, Yang" sort="Guo, Yang" uniqKey="Guo Y" first="Yang" last="Guo">Yang Guo</name><affiliation wicri:level="1"><nlm:affiliation>Department of Critical Care Medicine, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu 610000, Sichuan, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Critical Care Medicine, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu 610000, Sichuan</wicri:regionArea><wicri:noRegion>Sichuan</wicri:noRegion></affiliation></author><author><name sortKey="Huang, Xiaobo" sort="Huang, Xiaobo" uniqKey="Huang X" first="Xiaobo" last="Huang">Xiaobo Huang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Critical Care Medicine, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu 610000, Sichuan, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Critical Care Medicine, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu 610000, Sichuan</wicri:regionArea><wicri:noRegion>Sichuan</wicri:noRegion></affiliation></author></analytic><series><title level="j">Zhonghua wei zhong bing ji jiu yi xue</title><idno type="ISSN">2095-4352</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Antiviral Agents (therapeutic use)</term><term>China (epidemiology)</term><term>Coronavirus Infections (complications)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (epidemiology)</term><term>Drug Combinations (MeSH)</term><term>Humans (MeSH)</term><term>Liver Diseases (physiopathology)</term><term>Liver Diseases (virology)</term><term>Lopinavir (therapeutic use)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (complications)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (epidemiology)</term><term>Retrospective Studies (MeSH)</term><term>Ritonavir (therapeutic use)</term><term>Severity of Illness Index (MeSH)</term><term>Treatment Outcome (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen (MeSH)</term><term>Antiviraux (usage thérapeutique)</term><term>Association médicamenteuse (MeSH)</term><term>Chine (épidémiologie)</term><term>Humains (MeSH)</term><term>Indice de gravité de la maladie (MeSH)</term><term>Infections à coronavirus (complications)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Infections à coronavirus (épidémiologie)</term><term>Lopinavir (usage thérapeutique)</term><term>Maladies du foie (physiopathologie)</term><term>Maladies du foie (virologie)</term><term>Mâle (MeSH)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (complications)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Pneumopathie virale (épidémiologie)</term><term>Ritonavir (usage thérapeutique)</term><term>Résultat thérapeutique (MeSH)</term><term>Sujet âgé (MeSH)</term><term>Sujet âgé de 80 ans ou plus (MeSH)</term><term>Études rétrospectives (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Lopinavir</term><term>Ritonavir</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>China</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Maladies du foie</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Liver Diseases</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Infections à coronavirus</term><term>Lopinavir</term><term>Pneumopathie virale</term><term>Ritonavir</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Maladies du foie</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Liver Diseases</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Chine</term><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Drug Combinations</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Pandemics</term><term>Retrospective Studies</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Association médicamenteuse</term><term>Humains</term><term>Indice de gravité de la maladie</term><term>Mâle</term><term>Pandémies</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Études rétrospectives</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>République populaire de Chine</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b></p><p>To describe the characteristics of liver damage in severe coronavirus disease 2019 (COVID-19) patients in Sichuan area and the effect of antiviral drugs on liver function.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>The clinical data of severe COVID-19 patients admitted to Chengdu Public Health Clinical Medical Center from January 21 to February 24, 2020 were retrospectively collected, including demographic data, clinical manifestations and liver function changes within 1 week after admission to intensive care unit (ICU). The changes of liver function during the course of disease in severe COVID-19 patients were analyzed and summarized, and group analysis was performed.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>A total of 30 COVID-19 patients with complete clinical data were enrolled. The incidence of severe COVID-19 in elderly men was higher (60.0%), with median age of 61 (47, 79) years old, and those aged 80 or above accounted for 23.3%. The severe COVID-19 patients mainly presented with respiratory symptoms such as fever (96.7%), cough (80.0%) and dyspnea (66.7%). The alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBil) and prothrombin time (PT) of 30 patients were increased to various degrees within 1 week after ICU admission, and albumin (ALB) was decreased. (1) The patients were divided into two groups according to whether to take lopinavir/ritonavir (kaletra). It was shown that the incidence of liver dysfunction in patients taking kaletra was significantly higher than those who did not take kaletra (7-day abnormal rate of ALT was 54% vs. 33%, the abnormal rate of AST was 38% vs. 33%, the abnormal rate of TBil was 8% vs. 0%), but there were no statistical differences (all P > 0.05). (2) The patients were divided into normal dose group (500 mg, twice a day, n = 19) and reduced dose group (250 mg, twice a day, n = 5) according to the dosage of kaletra. It was shown that patients taking low-dose kaletra had a smaller effect on liver function within 1 week after ICU admission than those receiving normal dosage, and ALB, TBil in the reduced dose group were significantly lower than those in the normal dose group on the 2nd day after ICU admission [ALB (g/L): 33.3±2.0 vs. 37.5±4.0, TBil (μmol/L): 6.3±3.3 vs. 11.3±4.8, both P < 0.05].</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>Severe COVID-19 patients in Sichuan area suffered obvious liver damage in the early course of the disease and have a slower recovery. It is important to pay attention to avoid using drugs that can aggravate liver damage while treating the disease. If there is no alternative drug, liver protection treatment should be considered appropriately.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">32912404</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2095-4352</ISSN><JournalIssue CitedMedium="Print"><Volume>32</Volume><Issue>8</Issue><PubDate><Year>2020</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Zhonghua wei zhong bing ji jiu yi xue</Title><ISOAbbreviation>Zhonghua Wei Zhong Bing Ji Jiu Yi Xue</ISOAbbreviation></Journal><ArticleTitle>[Clinical characteristics of liver damage in 30 patients with severe coronavirus disease 2019 in Sichuan area].</ArticleTitle><Pagination><MedlinePgn>928-932</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3760/cma.j.cn121430-20200513-00656</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To describe the characteristics of liver damage in severe coronavirus disease 2019 (COVID-19) patients in Sichuan area and the effect of antiviral drugs on liver function.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The clinical data of severe COVID-19 patients admitted to Chengdu Public Health Clinical Medical Center from January 21 to February 24, 2020 were retrospectively collected, including demographic data, clinical manifestations and liver function changes within 1 week after admission to intensive care unit (ICU). The changes of liver function during the course of disease in severe COVID-19 patients were analyzed and summarized, and group analysis was performed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 30 COVID-19 patients with complete clinical data were enrolled. The incidence of severe COVID-19 in elderly men was higher (60.0%), with median age of 61 (47, 79) years old, and those aged 80 or above accounted for 23.3%. The severe COVID-19 patients mainly presented with respiratory symptoms such as fever (96.7%), cough (80.0%) and dyspnea (66.7%). The alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBil) and prothrombin time (PT) of 30 patients were increased to various degrees within 1 week after ICU admission, and albumin (ALB) was decreased. (1) The patients were divided into two groups according to whether to take lopinavir/ritonavir (kaletra). It was shown that the incidence of liver dysfunction in patients taking kaletra was significantly higher than those who did not take kaletra (7-day abnormal rate of ALT was 54% vs. 33%, the abnormal rate of AST was 38% vs. 33%, the abnormal rate of TBil was 8% vs. 0%), but there were no statistical differences (all P > 0.05). (2) The patients were divided into normal dose group (500 mg, twice a day, n = 19) and reduced dose group (250 mg, twice a day, n = 5) according to the dosage of kaletra. It was shown that patients taking low-dose kaletra had a smaller effect on liver function within 1 week after ICU admission than those receiving normal dosage, and ALB, TBil in the reduced dose group were significantly lower than those in the normal dose group on the 2nd day after ICU admission [ALB (g/L): 33.3±2.0 vs. 37.5±4.0, TBil (μmol/L): 6.3±3.3 vs. 11.3±4.8, both P < 0.05].</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Severe COVID-19 patients in Sichuan area suffered obvious liver damage in the early course of the disease and have a slower recovery. It is important to pay attention to avoid using drugs that can aggravate liver damage while treating the disease. If there is no alternative drug, liver protection treatment should be considered appropriately.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Tianlong</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu 610000, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Chengdu Public Health Clinical Medical Center, Chengdu 610000, Sichuan, China. Corresponding author: Huang Xiaobo, Email: drhuangxb@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Chengdu Public Health Clinical Medical Center, Chengdu 610000, Sichuan, China. Corresponding author: Huang Xiaobo, Email: drhuangxb@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yue</LastName><ForeName>Ruiming</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu 610000, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Sen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu 610000, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Chengdu Public Health Clinical Medical Center, Chengdu 610000, Sichuan, China. Corresponding author: Huang Xiaobo, Email: drhuangxb@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu 610000, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Xiaobo</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu 610000, Sichuan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Wei Zhong Bing Ji Jiu Yi Xue</MedlineTA><NlmUniqueID>101604552</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C558899">lopinavir-ritonavir drug combination</NameOfSubstance></Chemical><Chemical><RegistryNumber>2494G1JF75</RegistryNumber><NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008107" MajorTopicYN="N">Liver Diseases</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>11</Day><Hour>5</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32912404</ArticleId><ArticleId IdType="doi">10.3760/cma.j.cn121430-20200513-00656</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Oman</li><li>République populaire de Chine</li></country></list><tree><country name="République populaire de Chine"><noRegion><name sortKey="Li, Tianlong" sort="Li, Tianlong" uniqKey="Li T" first="Tianlong" last="Li">Tianlong Li</name></noRegion><name sortKey="Guo, Yang" sort="Guo, Yang" uniqKey="Guo Y" first="Yang" last="Guo">Yang Guo</name><name sortKey="Huang, Xiaobo" sort="Huang, Xiaobo" uniqKey="Huang X" first="Xiaobo" last="Huang">Xiaobo Huang</name><name sortKey="Lu, Sen" sort="Lu, Sen" uniqKey="Lu S" first="Sen" last="Lu">Sen Lu</name><name sortKey="Yue, Ruiming" sort="Yue, Ruiming" uniqKey="Yue R" first="Ruiming" last="Yue">Ruiming Yue</name></country><country name="Oman"><noRegion><name sortKey="Deng, Chao" sort="Deng, Chao" uniqKey="Deng C" first="Chao" last="Deng">Chao Deng</name></noRegion><name sortKey="Chen, Hong" sort="Chen, Hong" uniqKey="Chen H" first="Hong" last="Chen">Hong Chen</name><name sortKey="Du, Qing" sort="Du, Qing" uniqKey="Du Q" first="Qing" last="Du">Qing Du</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidSeniorV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000058 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000058 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidSeniorV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32912404
|texte= [Clinical characteristics of liver damage in 30 patients with severe coronavirus disease 2019 in Sichuan area].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32912404" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidSeniorV1
| This area was generated with Dilib version V0.6.37. |  |